Archiv - Dienstag 10. Juni 2008
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics
Veröffentlicht am Dienstag 10. Juni 2008 - 01.:54. - http://www.finanzen.net/Incyte Corporation (Nasdaq:INCY) announced clinical results presented today at the American Diabetes Association 68th Scientific Sessions of its Phase IIa trial of INCB13739, an orally bioavailable...
